Dr. Tal brings diverse entrepreneurial and scientific experience in biochemistry and molecular biology to the Tamarix Pharma leadership team. Prior to founding Tamarix in early 2021, Dr. Tal was co-founder and CEO of TPCera Ltd., which focused on developing novel immunomodulatory compounds to treat autoimmune diseases. During his tenure, Dr. Tal raised seed and round A funding to support the company’s technological, regulatory, clinical, financial, production, marketing, and business development activities. Dr. Tal was also the CEO of Gynamics, where he led all strategic and financial initiatives to advance the company’s medical device toward CE and FDA approval. Prior to his roles in the biotechnology industry, Dr. Tal served as Director of Business Development for the Technion – Israel Institute of Technology and for the Alfred Mann Institute for Biomedical Innovation.

Dr. Tal holds a PhD in Biochemistry and an MBA with specialization in Entrepreneurship and Finance from the Hebrew University of Jerusalem.

Dr. Zollmann joined Tamarix Pharma in 2021, bringing with her over 30 years of experience in the pharmaceutical industry. Prior to joining Tamarix, Dr. Zollmann was Senior VP of Chemistry, Manufacturing, and Controls (CMC) at Atox Bio for 7 years. Her previous experience includes Chiasma as Senior Director of CMC and more than 20 years in numerous leadership positions at Teva Pharmaceutical’s Global Innovative R&D Division, including as Director of the CMC Program for Small Molecules. During that time, she gained broad experience in global development of innovative pharmaceutical drug products, including CMC management and development, validation, technology transfer, regulatory strategy and initiatives, and professional CMC project evaluation and due diligence.

Dr. Zollmann holds a PhD in Electrochemistry from the Tel Aviv University, and a Master of Science degree in Analytical Chemistry and Bachelor of Science Honors in Chemistry from the University of Cape Town in South Africa.